PCI Synthesis, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PCI Synthesis, Inc. - overview
Established
1996
Location
Newburyport, MA, US
Primary Industry
Chemicals
About
PCI Synthesis, Inc. is a contract manufacturer specializing in the development and production of custom chemical synthesis for the pharmaceutical industry, providing innovative solutions to meet diverse client needs. Founded in 1996, PCI Synthesis, Inc. operates from its headquarters in Newburyport, Massachusetts, US.
The company focuses on custom chemical synthesis for pharmaceutical applications. In June 2018, PCI Synthesis was acquired by SEQENS, a portfolio company of Eurazeo, Ardian, and Mérieux Développement, with financial terms not disclosed. CEO Antoine Bertin leads the company, building on a history of expertise in the pharmaceutical sector. PCI Synthesis, Inc.
offers a range of custom chemical synthesis services tailored for the pharmaceutical industry. Their core capabilities include the development of active pharmaceutical ingredients (APIs), intermediates, and other specialized chemical compounds, catering to various therapeutic areas. By leveraging state-of-the-art technology and processes, the company serves a diverse clientele, including biotechnology firms and major pharmaceutical companies across North America and Europe. In 2018, PCI Synthesis reported a revenue of USD 32.
00 mn. The company utilizes a contract-based revenue model, engaging in agreements with clients that vary based on project scope and duration, ensuring a consistent revenue stream while addressing the complex needs of the pharmaceutical sector. Following its acquisition by SEQENS in June 2018, PCI Synthesis, Inc. aims to enhance its capabilities in pharmaceutical manufacturing.
The acquisition will facilitate an expanded offering for the pharmaceutical industry, supporting the company's strategic plan to introduce new products and services tailored to client needs. Plans for future growth include the development of innovative chemical synthesis solutions and potential expansions into new geographic markets across Europe and Asia by 2023. The financial backing from SEQENS will be utilized to strengthen R&D efforts and enhance manufacturing capabilities.
Current Investors
Seqens SAS
Primary Industry
Chemicals
Sub Industries
Biotechnology, Medicinal Chemicals & Botanicals
Website
www.pcisynthesis.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
PCI Synthesis, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | PCI Synthesis, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.